Susan Chang MD

Susan Chang, MD

Professor in Residence and Vice Chair of Neurological Surgery

Lai Wan Kan Endowed Chair

Director, Division of Neuro-Oncology

Director, UCSF Neuro-Oncology Gordon Murray Caregiver Program

Susan Chang, MD, is the Director of the UCSF Division of Neuro-Oncology and is an internationally recognized leader in the field of neurological malignancies. Her research expertise is in clinical trial design and the development of novel therapies and imaging biomarkers for brain tumors. Dr. Chang is the principal investigator and co-investigator on more than 20 active clinical trials that evaluate the wide spectrum of therapeutic interventions, spanning chemotherapy, targeted agents, immunotherapy, and convection-enhanced delivery of novel agents.

Dr. Chang also has a strong interest in quality-of-life issues faced by patients with brain tumors and their families. She is the founder and Director of the UCSF Neuro-Oncology Gordon Murray Caregiver Program, which focuses on providing resources and support to the caregivers of brain tumor patients.

Dr. Chang is currently is the site PI of an NIH-funded Adult Brain Tumor Consortium and a member of the Brain Malignancy Steering Committee and Chair of the Developmental Therapeutics Study Section at the NIH. She is also a Program Leader for the UCSF Comprehensive Cancer Center. She was a past president of the Society for Neuro-Oncology as well as a member of the Board of Scientific Counselors for the NCI.

Video: Susan Chang, Director of Neuro-Oncology

Education, Training, and Previous Positions

1981: BS, University of British Columbia
1985: MD, University of British Columbia
1985-1986: Internship, Pasqua Hospital, Regina, Saskatchewan, Canada
1986-1987: Residency in Internal Medicine, Plains Health Centre, Regina, Saskatchewan, Canada
1987-1989: Residency in Internal Medicine, Toronto General Hospital, Ontario, Canada
1989-1991: Fellowship in Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada
1991-1992: Lecturer in Internal Medicine, St Michael's Hospital, Toronto, Ontario, Canada
1992: Director of Palliative Care, Department of Medicine, St Michael's Hospital, Toronto, Ontario, Canada
1992-1993: Fellowship in Neuro-Oncology, University of California, San Francisco
1993-1994: Clinical Instructor, Neuro-Oncology, Department of Neurosurgery, UCSF
1994-1996: Assistant Clinical Professor, Neuro-Oncology, Department of Neurosurgery, UCSF
1996-1998: Assistant Professor in Residence, Neuro-Oncology, Department of Neurosurgery, UCSF
1998-2004: Associate Professor in Residence, Neuro-Oncology, Department of Neurosurgery, UCSF
2004-present: Professor in Residence, Neuro-Oncology, Department of Neurosurgery, UCSF

Selected Professional Memberships and Appointments

President of the Society for Neuro-Oncology
American College of Surgeons Oncology Group
International Society of Neuro-Oncology
Canadian Medical Association
American Society of Clinical Oncology
Member of the College of Physicians and Surgeons of Ontario
Fellow of the Royal College of Physicians and Surgeons of Canada

Selected Recent Publications

Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 Apr 5. doi: 10.1093/neuonc/noy053. [Epub ahead of print] PubMed PMID: 29660006.

Vasudevan HN, Braunstein SE, Phillips JJ, Pekmezci M, Tomlin BA, Wu A, Reis GF, Magill ST, Zhang J, Feng FY, Nicholaides T, Chang SM, Sneed PK, McDermott MW, Berger MS, Perry A, Raleigh DR. Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation. Cell Rep. 2018 Mar 27;22(13):3672-3683. doi: 10.1016/j.celrep.2018.03.013. PubMed PMID: 29590631.

Choi S, Yu Y, Grimmer MR, Wahl M, Chang SM, Costello JF. Temozolomide-associated Hypermutation in Gliomas. Neuro Oncol. 2018 Feb 14. doi: 10.1093/neuonc/noy016. [Epub ahead of print] PubMed PMID: 29452419.

Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran R, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018 Apr 1;36(10):1020-1044. doi: 10.1200/JCO.2017.77.0446. Epub 2018 Jan 30. PubMed PMID: 29380678.

Alexander BM, Brown PD, Ahluwalia MS, Aoyama H, Baumert BG, Chang SM, Gaspar LE, Kalkanis SN, Macdonald DR, Mehta MP, Soffietti R, Suh JH, van den Bent MJ, Vogelbaum MA, Wefel JS, Lee EQ, Wen PY; Response Assessment in Neuro-Oncology (RANO) group. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018 Jan;19(1):e33-e42. doi: 10.1016/S1470-2045(17)30692-7. Review. PubMed PMID: 29304360.

Park I, Larson PEZ, Gordon JW, Carvajal L, Chen HY, Bok R, Van Criekinge M, Ferrone M, Slater JB, Xu D, Kurhanewicz J, Vigneron DB, Chang S, Nelson SJ. Development of methods and feasibility of using hyperpolarized carbon-13 imaging data for evaluating brain metabolism in patient studies. Magn Reson Med. 2018 Jan 10. doi: 10.1002/mrm.27077. [Epub ahead of print] PubMed PMID: 29322616.

Camidge DR, Lee EQ, Lin NU, Margolin K, Ahluwalia MS, Bendszus M, Chang SM, Dancey J, de Vries EGE, Harris GJ, Hodi FS, Lassman AB, Macdonald DR, Peereboom DM, Schiff D, Soffietti R, van den Bent MJ, Wefel JS, Wen PY. Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncol. 2018 Jan;19(1):e20-e32. doi: 10.1016/S1470-2045(17)30693-9. Review. PubMed PMID: 29304358.

Wallace RM, Lai Y, Doty JB, Chen CC, Vora NM, Blanton JD, Chang SS, Cleaton JM, Pei KJC. Initial pen and field assessment of baits to use in oral rabies vaccination of Formosan ferret-badgers in response to the re-emergence of rabies in Taiwan. PLoS One. 2018 Jan 2;13(1):e0189998. doi: 10.1371/journal.pone.0189998. eCollection 2018. PubMed PMID: 29293591; PubMed Central PMCID: PMC5749709.

Hayes J, Yu Y, Jalbert LE, Mazor T, Jones LE, Wood MD, Walsh KM, Bengtsson H, Hong C, Oberndorfer S, Roetzer T, Smirnov IV, Clarke JL, Aghi MK, Chang SM, Nelson SJ, Woehrer A, Phillips JJ, Solomon DA, Costello JF. Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro Oncol. 2018 Apr 9;20(5):632-641. doi: 10.1093/neuonc/nox205. PubMed PMID: 29077933; PubMed Central PMCID: PMC5892142.

Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res. 2018 Jan 15;24(2):295-305. doi: 10.1158/1078-0432.CCR-17-0963. Epub 2017 Oct 26. PubMed PMID: 29074604.

Li Y, Lafontaine M, Chang S, Nelson SJ. Comparison between Short and Long Echo Time Magnetic Resonance Spectroscopic Imaging at 3T and 7T for Evaluating Brain Metabolites in Patients with Glioma. ACS Chem Neurosci. 2018 Jan 17;9(1):130-137. doi: 10.1021/acschemneuro.7b00286. Epub 2017 Oct 16. PubMed PMID: 29035503; PubMed Central PMCID: PMC5771946.

Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF. Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. J Neurooncol. 2018 Jan;136(1):79-86. doi: 10.1007/s11060-017-2624-4. Epub 2017 Oct 7. PubMed PMID: 28988377; PubMed Central PMCID: PMC5756101.

Autry A, Phillips JJ, Maleschlijski S, Roy R, Molinaro AM, Chang SM, Cha S, Lupo JM, Nelson SJ. Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. Transl Oncol. 2017 Dec;10(6):895-903. doi: 10.1016/j.tranon.2017.08.009. Epub 2017 Sep 22. PubMed PMID: 28942218; PubMed Central PMCID: PMC5612804.

Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Marra MA, Cairncross JG, Perry A, Nelson SJ, Chang SM, Bollen AW, Molinaro AM, Bengtsson H, Olshen AB, Weiss S, Phillips JJ, Luchman HA, Costello JF. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10743-10748. doi: 10.1073/pnas.1708914114. Epub 2017 Sep 15. PubMed PMID: 28916733; PubMed Central PMCID: PMC5635900.

Das S, Kim AH, Chang S, Berger MS. Management of Elderly Patients with Glioblastoma after CE.6. Front Oncol. 2017 Aug 30;7:196. doi: 10.3389/fonc.2017.00196. eCollection 2017. PubMed PMID: 28913179; PubMed Central PMCID: PMC5582080.

Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD; GBM AGILE Network. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clin Cancer Res. 2018 Feb 15;24(4):737-743. doi: 10.1158/1078-0432.CCR-17-0764. Epub 2017 Aug 16. Review. PubMed PMID: 28814435.

Wahl M, Anwar M, Hess CP, Chang SM, Lupo JM. Relationship between radiation dose and microbleed formation in patients with malignant glioma. Radiat Oncol. 2017 Aug 10;12(1):126. doi: 10.1186/s13014-017-0861-5. PubMed PMID: 28797254; PubMed Central PMCID: PMC5553662.

Wahl M, Chang SM, Phillips JJ, Molinaro AM, Costello JF, Mazor T, Alexandrescu S, Lupo JM, Nelson SJ, Berger M, Prados M, Taylor JW, Butowski N, Clarke JL, Haas-Kogan D. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. Cancer. 2017 Dec 1;123(23):4631-4639. doi: 10.1002/cncr.30909. Epub 2017 Jul 31. PubMed PMID: 28759109; PubMed Central PMCID: PMC5693663.

Anwar M, Molinaro AM, Morin O, Chang SM, Haas-Kogan DA, Nelson SJ, Lupo JM. Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI. Radiat Res. 2017 Sep;188(3):303-313. doi: 10.1667/RR14662.1. Epub 2017 Jul 19. PubMed PMID: 28723274; PubMed Central PMCID: PMC5628052.

Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol. 2017 Jul 20;35(21):2439-2449. doi: 10.1200/JCO.2017.72.7511. Epub 2017 Jun 22. Review. PubMed PMID: 28640707; PubMed Central PMCID: PMC5516482.

van den Bent MJ, Smits M, Kros JM, Chang SM. Diffuse Infiltrating Oligodendroglioma and Astrocytoma. J Clin Oncol. 2017 Jul 20;35(21):2394-2401. doi: 10.1200/JCO.2017.72.6737. Epub 2017 Jun 22. Review. PubMed PMID: 28640702.

Flanigan PM, Jahangiri A, Kuang R, Truong A, Choi S, Chou A, Rick JW, Chang SM, Molinaro AM, McDermott MW, Berger MS, Aghi MK. Improved Survival with Decreased Wait Time to Surgery in Glioblastoma Patients Presenting with Seizure. Neurosurgery. 2017 Nov 1;81(5):824-833. doi: 10.1093/neuros/nyx084. PubMed PMID: 28541497.

Warren KE, Vezina G, Poussaint TY, Warmuth-Metz M, Chamberlain MC, Packer RJ, Brandes AA, Reiss M, Goldman S, Fisher MJ, Pollack IF, Prados MD, Wen PY, Chang SM, Dufour C, Zurakowski D, Kortmann RD, Kieran MW. Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. Neuro Oncol. 2018 Jan 10;20(1):13-23. doi: 10.1093/neuonc/nox087. PubMed PMID: 28449033; PubMed Central PMCID: PMC5761545.

Chang SM. Barriers to the development of drugs for primary brain tumors. Clin Adv Hematol Oncol. 2017 Feb;15(2):104-107. PubMed PMID: 28398278.

Chang SM, Chakavarti A, Bell EH. Reply to letter on results of NRG Oncology RTOG 9813. Neuro Oncol. 2017 May 1;19(5):739. doi: 10.1093/neuonc/nox008. PubMed PMID: 28340219; PubMed Central PMCID: PMC5464454.

van den Bent MJ, Weller M, Wen PY, Kros JM, Aldape K, Chang S. A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. Neuro Oncol. 2017 May 1;19(5):614-624. doi: 10.1093/neuonc/now277. Review. PubMed PMID: 28339700; PubMed Central PMCID: PMC5464438.

Jalbert LE, Elkhaled A, Phillips JJ, Neill E, Williams A, Crane JC, Olson MP, Molinaro AM, Berger MS, Kurhanewicz J, Ronen SM, Chang SM, Nelson SJ. Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma. Sci Rep. 2017 Mar 22;7:44792. doi: 10.1038/srep44792. PubMed PMID: 28327577; PubMed Central PMCID: PMC5361089.

Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemother Pharmacol. 2017 Mar;79(3):603-610. doi: 10.1007/s00280-017-3247-3. Epub 2017 Feb 23. PubMed PMID: 28233053.

Neill E, Luks T, Dayal M, Phillips JJ, Perry A, Jalbert LE, Cha S, Molinaro A, Chang SM, Nelson SJ. Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma. J Neurooncol. 2017 Mar;132(1):171-179. doi: 10.1007/s11060-016-2355-y. Epub 2017 Jan 25. PubMed PMID: 28124178; PubMed Central PMCID: PMC5373029.

Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 Mar;132(1):181-188. doi: 10.1007/s11060-016-2357-9. Epub 2017 Jan 23. PubMed PMID: 28116649; PubMed Central PMCID: PMC5588922.

Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, Penas-Prado M, Robins HI, Belanger K, Schultz C, Hunter G, Mehta M. Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. Neuro Oncol. 2017 Feb 1;19(2):252-258. doi: 10.1093/neuonc/now236. PubMed PMID: 27994066; PubMed Central PMCID: PMC5463834.

Oberheim Bush NA, Chang S. Treatment Strategies for Low-Grade Glioma in Adults. J Oncol Pract. 2016 Dec;12(12):1235-1241. PubMed PMID: 27943684.

Sulman EP, Ismaila N, Chang SM. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. J Oncol Pract. 2017 Feb;13(2):123-127. doi: 10.1200/JOP.2016.018937. Epub 2016 Nov 29. PubMed PMID: 27907278.

Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, Galanis E, Gilbert M, Gondi V, Lovely M, Mehta M, Mumber MP, Sloan A, Chang SM. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. J Clin Oncol. 2017 Jan 20;35(3):361-369. doi: 10.1200/JCO.2016.70.7562. Epub 2016 Nov 28. Review. PubMed PMID: 27893327.

Nelson SJ, Li Y, Lupo JM, Olson M, Crane JC, Molinaro A, Roy R, Clarke J, Butowski N, Prados M, Cha S, Chang SM. Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab. J Neurooncol. 2016 Oct;130(1):171-179. Epub 2016 Aug 17. PubMed PMID: 27535746; PubMed Central PMCID: PMC5069332.

Nelson SJ, Kadambi AK, Park I, Li Y, Crane J, Olson M, Molinaro A, Roy R, Butowski N, Cha S, Chang S. Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen. Neuro Oncol. 2017 Mar 1;19(3):430-439. doi: 10.1093/neuonc/now159. PubMed PMID: 27576874; PubMed Central PMCID: PMC5464305.

Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol. 2017 Feb 1;19(2):242-251. doi: 10.1093/neuonc/now176. PubMed PMID: 27571885; PubMed Central PMCID: PMC5464133.

Barajas RF Jr, Butowski NA, Phillips JJ, Aghi MK, Berger MS, Chang SM, Cha S. The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma. Acad Radiol. 2016 Sep;23(9):1073-82. doi: 10.1016/j.acra.2016.04.004. Epub 2016 Jul 18. PubMed PMID: 27443507; PubMed Central PMCID: PMC5571825.

Chang SM, Cahill DP, Aldape KD, Mehta MP. Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. Am Soc Clin Oncol Educ Book. 2016;35:75-81. doi: 10.14694/EDBK_158869. Review. PubMed PMID: 27249688.

Bush NA, Chang SM, Berger MS. Current and future strategies for treatment of glioma. Neurosurg Rev. 2017 Jan;40(1):1-14. doi: 10.1007/s10143-016-0709-8. Epub 2016 Apr 16. Review. PubMed PMID: 27085859.

Koekkoek JA, Chang S, Taphoorn MJ. Palliative care at the end-of-life in glioma patients. Handb Clin Neurol. 2016;134:315-26. doi: 10.1016/B978-0-12-802997-8.00019-0. Review. PubMed PMID: 26948363.

Jalbert LE, Neill E, Phillips JJ, Lupo JM, Olson MP, Molinaro AM, Berger MS, Chang SM, Nelson SJ. Magnetic resonance analysis of malignant transformation in recurrent glioma. Neuro Oncol. 2016 Aug;18(8):1169-79. doi: 10.1093/neuonc/now008. Epub 2016 Feb 23. PubMed PMID: 26911151; PubMed Central PMCID: PMC4933480.